Suburban Propane Partners: Q1 Earnings Insights

  Suburban Propane Partners (NYSE:SPH) reported its Q1 earnings results on Thursday, February 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

 

Suburban Propane Partners (NYSE:SPH) reported its Q1 earnings results on Thursday, February 3, 2022 at 07:30 AM.

Here’s what investors need to know about the announcement.

Check out this: Insiders Buying Charter Communications And 3 More Stocks

Earnings

Suburban Propane Partners missed estimated earnings by 50.72%, reporting an EPS of $0.34 versus an estimate of $0.69, which surprised analysts.

Revenue was up $70.22 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.49, which was followed by a 1.44% increase in the share price the next day.

Here’s a look at Suburban Propane Partners’s past performance:

 

Quarter Q4 2021 Q3 2021 Q2 2021 Q1 2021
EPS Estimate -0.68 -0.42 1.73 0.55
EPS Actual -0.19 -0.16 2.02 0.61
Revenue Estimate 174.61M 218.62M 431.89M 321.75M
Revenue Actual 208.24M 238.09M 537.24M 305.19M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Orphazyme Announces Publication of Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-pick Disease Type C in the Journal of Inherited Metabolic Disease; Trial Demonstrated a Statistically Significant and Clinically Meaningful Treatment Effect o…

Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced that results from a Phase 2/3 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) have been published in the peer-reviewed Journal of Inherited Metabolic Disease (JIMD). The online publication is available here.

ORPH